Dr. Asit Parikh, MD, SVP, and head of the Gastrointestinal Therapeutic Area at Takeda Pharmaceutical Company Limited discusses new data presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab (Entyvio®) for use during maintenance therapy in adult patients with moderately to severely active Crohn’s disease (CD).
Asit Parikh, M.D., Ph.D., is the senior vice president and head of the Gastrointestinal Therapeutic Area at Takeda Pharmaceuticals. Asit earned his Ph.D. in biochemistry and his M.D. from Vanderbilt University and was a resident in internal medicine at the University of Pennsylvania. He then completed subspecialty training in gastroenterology at the Massachusetts General Hospital, with postdoctoral work in cancer biology at Massachusetts Institute of Technology. He also remains actively engaged in the practice of gastroenterology and internal medicine as a part-time coverage staff physician at Newton-Wellesley Hospital.